×
About 35,633 results
Hereditary Cancer Syndromes and Risk Assessment ACOG COMMITTEE OPINION, Number 793
https://journals.lww.com/greenjournal/Fulltext/2019/12000/Hereditary_Cancer_Syndromes_and_Risk_Assessment_.39.aspx
Obstetrics & Gynecology; ACOG

Nov 30th, 2019 - A hereditary cancer syndrome is a genetic predisposition to certain types of cancer, often with onset at an early age, caused by inherited pathogenic variants in one or more genes. Most hereditary cancer syndromes exhibit autosomal dominant inheritance. The most common hereditary cancer syndromes related to women’s cancer include hereditary breast and ovarian cancer syndrome, Lynch syndrome, Li...

Update on the Management of Constipation
https://jamanetwork.com/journals/jama/article-abstract/2754106
JAMA Wald A

Nov 16th, 2019 - Chronic constipation is very common. The most recent estimate of clinician visits attributable to constipation were from 2001 to 2004 and reported more than 8 million clinician visits in the United States, with most occurring in adult primary care settings (33%) followed by pediatric (21%) and gastroenterologist (14%) offices.1 These encounters result in large expenditures for nonprescription l...

Short-Term Survival in Patients Aged 85 Years and Older After Colorectal Cancer Surgery
https://ascopost.com/news/november-2019/short-term-survival-in-patients-aged-85-years-and-older-after-colorectal-cancer-surgery/
ASCO Post;

Nov 11th, 2019 - Results from a preliminary research study showed the majority of patients aged 85 years and older were still alive in the short-term after undergoing segmental colectomy for stage II and III colon cancer. Kaur et al presented these findings at the American College of Surgeons Clinical Congress 2019.

Addition of Durvalumab to Etoposide Plus Platinum Chemotherapy for Extensive-Stage SCLC
https://ascopost.com/podcasts/addition-of-durvalumab-to-etoposide-plus-platinum-chemotherapy-for-extensive-stage-sclc/
ASCO Post;

Nov 10th, 2019 - This week, we’ll review an interim analysis of the CASPIAN trial, which evaluated the addition of durvalumab to etoposide plus platinum chemotherapy for extensive-stage small cell lung cancer. Then, we’ll talk about two recently issued guidelines on screening for colorectal cancer. Lastly, we’ll summarize some recent FDA approvals and announcements.

Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults: A Guidance Statement From the American College of Physicians
https://annals.org/aim/fullarticle/2754194/screening-colorectal-cancer-asymptomatic-average-risk-adults-guidance-statement-from
Annals of Internal Medicine;

Nov 5th, 2019 - The goal of this American College of Physicians (ACP) guidance statement is to guide clinicians on age to start and stop CRC screening, frequency of screening, and optimal screening test in asymptomatic, average-risk adults, based on a critical review of existing guidelines and their evidence reviews.

Chronic Constipation: New Insights, Better Outcomes?
https://www.ncbi.nlm.nih.gov/pubmed/31609241
Lancet Gastroenterology Hepatology; Schiller LR

Oct 31st, 2019 - Constipation is a symptom that affects around 11-20% of the adult population yearly. Most physicians consider infrequency of defecation as a hallmark of constipation. However, most patients view excessive straining as the biggest component of constipation and only a minority of patients with constipation have infrequent bowel movements.

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
https://www.nejm.org/doi/full/10.1056/NEJMoa1908075?query=featured_hematology-oncology
The New England Journal of Medicine; Kopetz, S. et. al.

Oct 23rd, 2019 - BACKGROUND Patients with metastatic colorectal cancer with the BRAF V600E mutation have a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial therapy. Inhibition of BRAF alone has limited activity because of pathway reactivation through epidermal growth factor receptor signaling. METHODS In this open-label, phase 3 trial, we enrolled 665 patients with B...

FDA approves niraparib for HRD-positive advanced ovarian cancer
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-hrd-positive-advanced-ovarian-cancer

Oct 22nd, 2019 - On October 23, 2019,the Food and Drug Administration approved niraparib (ZEJULA, Tesaro, Inc.) for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD)-positive status. HRD is defined by either a deleterious or suspected deleterious BRCA mu...

Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group
https://annals.org/aim/fullarticle/2753604/management-nonvariceal-upper-gastrointestinal-bleeding-guideline-recommendations-from-international-consensus
Annals of Internal Medicine; Barkun, A. et. al.

Oct 21st, 2019 - Description: This update of the 2010 International Consensus Recommendations on the Management of Patients With Nonvariceal Upper Gastrointestinal Bleeding (UGIB) refines previous important statements and presents new clinically relevant recommendations. Methods: An international multidisciplinary group of experts developed the recommendations. Data sources included evidence summarized in ...

Janssen Announces U.S. FDA Approval of STELARA® (ustekinumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
https://www.prnewswire.com/news-releases/janssen-announces-us-fda-approval-of-stelara-ustekinumab-for-the-treatment-of-adults-with-moderately-to-severely-active-ulcerative-colitis-300941913.html

Oct 20th, 2019 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration's (FDA) approval of STELARA® (ustekinumab) for the treatment of adult patients with moderately to severely active ulcerative colitis. The approval for this new indication is based on the pivotal Phase 3 UNIFI clinical trial which achieved its primary endpoint of clinical remission. Re...

Gastric Cancer Treatment (PDQ®)–Health Professional Version Go to Patient Version
https://www.cancer.gov/types/stomach/hp/stomach-treatment-pdq

Oct 10th, 2019 - Gastric cancer treatment options depend on extent of disease and may include radical surgery, chemotherapy, radiation, and immunotherapy. Get detailed information about the diagnosis, treatment, and prognosis of newly diagnosed and recurrent gastric cancer in this clinician summary.

A Comparison of the Efficacy of Enema Solutions in Pediatric Emergency Department Patients
https://www.ncbi.nlm.nih.gov/pubmed/31594739
Journal of Emergency Medicine; Anderson J, et al

Oct 4th, 2019 - Children presenting to pediatric emergency departments (EDs) are frequently given enemas for relief of constipation symptoms; there is very little literature guiding solution selection.

Opioid Use Disorder: Medical Treatment Options
https://www.aafp.org/afp/2019/1001/p416.html
American Family Physician; Coffa, D. et. al.

Sep 30th, 2019 - Opioid use disorder is highly prevalent and can be fatal. At least 2.1 million Americans 12 years and older had opioid use disorder in 2016, and approximately 47,000 Americans died from opioid overdoses in 2017. Opioid use disorder is a chronic relapsing condition, the treatment of which falls within the scope of practice of family physicians. With appropriate medication-assisted treatment, pat...

FDA approves treatment for adults and children with all genotypes of hepatitis C and compensated cirrhosis that shortens duration of treatment to eight weeks
https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-adults-and-children-all-genotypes-hepatitis-c-and-compensated-cirrhosis

Sep 25th, 2019 - The U.S. Food and Drug Administration today expanded the approval of Mavyret (glecaprevir and pibrentasvir) tablets for an eight-week duration for the treatment of adults and children ages 12 years and older or weighing at least 99 pounds who have chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection and compensated cirrhosis and have not been previously treated for HCV (treatme...

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
https://www.nejm.org/doi/full/10.1056/NEJMoa1905725
The New England Journal of Medicine; Sands, B. et. al.

Sep 25th, 2019 - BACKGROUND Biologic therapies are widely used in patients with ulcerative colitis. Head-to-head trials of these therapies in patients with inflammatory bowel disease are lacking. METHODS In a phase 3b, double-blind, double-dummy, randomized trial conducted at 245 centers in 34 countries, we compared vedolizumab with adalimumab in adults with moderately to severely active ulcerative colitis...

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
https://www.nejm.org/doi/full/10.1056/NEJMoa1900750
The New England Journal of Medicine; Sands. B., et al

Sep 25th, 2019 - he efficacy of ustekinumab, an antagonist of the p40 subunit of interleukin-12 and interleukin-23, as induction and maintenance therapy in patients with ulcerative colitis is unknown. METHODS We evaluated ustekinumab as 8-week induction therapy and 44-week maintenance therapy in patients with moderate-to-severe ulcerative colitis. A total of 961 patients were randomly assigned to receive an...

Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline
https://annals.org/aim/fullarticle/2751913/prevention-diagnosis-evaluation-treatment-hepatitis-c-virus-infection-chronic-kidney

Sep 23rd, 2019 - Description: The Kidney Disease: Improving Global Outcomes (KDIGO) 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C virus (HCV) infection in chronic kidney disease (CKD) is an extensive update of KDIGO's 2008 guideline on HCV infection in CKD. This update reflects the major advances since the introduction of direct-acting antivirals (DAAs...

Alarming number of heart infections tied to opioid epidemic
https://newsroom.heart.org/news/alarming-number-of-heart-infections-tied-to-opioid-epidemic

Sep 17th, 2019 - An alarming number of people nationwide are developing infections of either the heart’s inner lining or valves, known as infective endocarditis, in large part, due to the current opioid epidemic. This new trend predominantly affects young, white, poor men who also have higher rates of HIV, hepatitis C and alcohol abuse, according to new research published in the Journal of the American Heart As...

Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial
https://www.bmj.com/content/366/bmj.l5016
The BMJ;

Sep 10th, 2019 - Objective To assess the effects of Helicobacter pylori treatment, vitamin supplementation, and garlic supplementation in the prevention of gastric cancer. Design Blinded randomized placebo controlled trial. Setting Linqu County, Shandong province, China. Participants 3365 residents of a high risk region for gastric cancer. 2258 participants seropositive for antibodies to H pylori were ...